Trials / Completed
CompletedNCT06076486
A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 202 (actual)
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical · Industry
- Sex
- Female
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 3, multicenter, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of elagolix tablets versus placebo in premenopausal women with moderate or severe endometriosis-associated pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elagolix | Elagolix 200 mg tablets administered orally BID |
| DRUG | Elagolix placebo | Elagolix placebo administered orally BID |
Timeline
- Start date
- 2023-09-14
- Primary completion
- 2024-11-22
- Completion
- 2025-04-02
- First posted
- 2023-10-10
- Last updated
- 2025-09-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06076486. Inclusion in this directory is not an endorsement.